CA2724279C - Anti-il-6/il-6r antibodies and methods of use thereof - Google Patents
Anti-il-6/il-6r antibodies and methods of use thereof Download PDFInfo
- Publication number
- CA2724279C CA2724279C CA2724279A CA2724279A CA2724279C CA 2724279 C CA2724279 C CA 2724279C CA 2724279 A CA2724279 A CA 2724279A CA 2724279 A CA2724279 A CA 2724279A CA 2724279 C CA2724279 C CA 2724279C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12740308P | 2008-05-13 | 2008-05-13 | |
| US61/127,403 | 2008-05-13 | ||
| US19415608P | 2008-09-25 | 2008-09-25 | |
| US61/194,156 | 2008-09-25 | ||
| PCT/US2009/043734 WO2009140348A2 (en) | 2008-05-13 | 2009-05-13 | Anti-il-6/il-6r antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2724279A1 CA2724279A1 (en) | 2009-11-19 |
| CA2724279C true CA2724279C (en) | 2017-03-07 |
Family
ID=41319307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2724279A Active CA2724279C (en) | 2008-05-13 | 2009-05-13 | Anti-il-6/il-6r antibodies and methods of use thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US8034344B2 (https=) |
| EP (1) | EP2297202B1 (https=) |
| JP (5) | JP2011520898A (https=) |
| CN (1) | CN102089326B (https=) |
| AU (1) | AU2009246430B2 (https=) |
| CA (1) | CA2724279C (https=) |
| DK (1) | DK2297202T3 (https=) |
| ES (1) | ES2564635T3 (https=) |
| IL (1) | IL209277A (https=) |
| MX (1) | MX2010012031A (https=) |
| WO (1) | WO2009140348A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006035617A1 (de) * | 2006-07-31 | 2008-02-21 | Siemens Ag | Automatische Bestimmung von Tumorlast |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| EP2174667B1 (en) * | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
| MX2010012031A (es) | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| WO2012098238A1 (en) | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| MX342810B (es) * | 2011-03-03 | 2016-10-13 | Apexigen Inc | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. |
| WO2013075027A2 (en) * | 2011-11-17 | 2013-05-23 | Emergent Product Development Seattle, Llc | Anti-sil6xr complex binding domains and methods of use |
| KR101510302B1 (ko) | 2012-05-11 | 2015-04-10 | 가톨릭대학교 산학협력단 | Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제 |
| US10504132B2 (en) | 2012-11-27 | 2019-12-10 | American Express Travel Related Services Company, Inc. | Dynamic rewards program |
| CA2942546C (en) | 2014-03-17 | 2022-11-22 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| CA2991637C (en) | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| WO2017079443A1 (en) * | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
| KR20250011241A (ko) * | 2016-05-05 | 2025-01-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Il-6 및 cd126을 표적으로하는 dna 단일 클론 항체 |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| CN117045784A (zh) | 2016-12-14 | 2023-11-14 | 比奥拉治疗股份有限公司 | 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病 |
| GB2558223B (en) | 2016-12-22 | 2021-03-31 | Heraeus Electro Nite Int | Method for measuring a temperature of a molten metal bath |
| KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| CN111051343B (zh) | 2017-09-13 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Il-6r抗体、其抗原结合片段及医药用途 |
| EP3735421A4 (en) | 2018-01-05 | 2021-09-22 | Corvidia Therapeutics, Inc. | METHOD OF TREATMENT OF IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNSUPPRESSION |
| CN112423773A (zh) * | 2018-05-15 | 2021-02-26 | 鹿特丹伊拉斯谟大学医疗中心 | 用于寨卡病毒感染预后的治疗和生物标志物 |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US20210363233A1 (en) | 2018-06-20 | 2021-11-25 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| SG11202111742QA (en) | 2019-04-24 | 2021-11-29 | Sanofi Biotechnology | Methods of diagnosis and treatment of rheumatoid arthritis |
| CA3142710A1 (en) | 2019-06-04 | 2020-12-10 | Sanofi Biotechnology | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| US20230390391A1 (en) | 2020-01-22 | 2023-12-07 | Regents Of The University Of Minnesota | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| IL296276A (en) | 2020-03-10 | 2022-11-01 | Tiziana Life Sciences Plc | Compositions of il-6/il-6r antibodies and methods of use thereof |
| WO2021207697A1 (en) | 2020-04-10 | 2021-10-14 | Cantex Pharmaceuticals, Inc. | Treatment of acute lung injury |
| IL297697A (en) * | 2020-06-17 | 2022-12-01 | Tiziana Life Sciences Plc | Preparations and methods for improving chimeric antigen receptor t cell therapies |
| US20240316008A1 (en) | 2020-06-22 | 2024-09-26 | Tranquis Therapeutics, Inc. | Treatment of systemic immune activation syndromes |
| AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
| WO2022040604A1 (en) | 2020-08-21 | 2022-02-24 | BioAge Labs, Inc. | Use of dp1 receptor antagonists for the treatment of viral respiratory tract infections and dysregulated immune response in aged and aging patients |
| AU2021338354A1 (en) | 2020-09-02 | 2023-04-20 | Serhat GUMRUKCU | Expanded memory subsets of gamma delta T cells for immunotherapy |
| US20220332822A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| JP2024530943A (ja) | 2021-08-06 | 2024-08-27 | アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ | がんの処置のための方法 |
| WO2024126805A1 (en) | 2022-12-15 | 2024-06-20 | Aarhus Universitet | Synthetic activation of multimeric transmembrane receptors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428979B1 (en) | 1988-01-22 | 2002-08-06 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| IL88375A (en) | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method |
| ES2093017T3 (es) | 1989-07-20 | 1996-12-16 | Tadamitsu Kishimoto | Anticuerpo contra el receptor de la interleuquina-6 humana. |
| WO1991007986A1 (en) | 1989-12-04 | 1991-06-13 | Schering Corporation | Method of treating septic shock |
| US5795965A (en) | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JPH04325095A (ja) | 1991-04-26 | 1992-11-13 | Tosoh Corp | 抗ヒトｉｌ−６モノクロ−ナル抗体及び該抗体を使用するｉｌ−６の測定方法 |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU7967294A (en) | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| DE69534075T2 (de) | 1994-06-07 | 2005-07-21 | Chugai Seiyaku K.K. | Vorbeugungs- und heilmittel für erkrankungen, die durch fibrin- oder thrombusbildung hervorgerufen werden |
| ES2384222T3 (es) * | 1994-10-07 | 2012-07-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibición del crecimiento anómalo de células sinoviales utilizando un antagonista de IL-6 como principio activo |
| CN1306963C (zh) | 1994-10-21 | 2007-03-28 | 岸本忠三 | 用于治疗il－6产生所致疾病的药物组合物 |
| CA2230949C (en) * | 1995-09-28 | 2009-11-17 | Judith Chebath | Synthetic peptides that inhibit il-6 activity |
| JPH1066582A (ja) | 1996-08-27 | 1998-03-10 | Tosoh Corp | Ｉｌ−６のヘリックスｄ領域を認識する抗体の遺伝子断片等 |
| EP2322216A1 (en) | 1997-03-21 | 2011-05-18 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| CN100374159C (zh) | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
| US6261250B1 (en) | 1998-08-20 | 2001-07-17 | Rle Corporation | Method and apparatus for enhancing cardiovascular activity and health through rhythmic limb elevation |
| ES2276525T3 (es) | 1998-08-24 | 2007-06-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo. |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| JP4325095B2 (ja) | 2000-09-08 | 2009-09-02 | 株式会社デンソー | ＳｉＣ素子の製造方法 |
| CN1259973C (zh) | 2000-10-25 | 2006-06-21 | 中外制药株式会社 | 含有il－6拮抗剂作为有效成分的牛皮癣的预防或治疗剂 |
| AU2000279624A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤 |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| KR100899357B1 (ko) | 2001-04-27 | 2009-05-26 | 다이셀 가가꾸 고교 가부시끼가이샤 | 다환식구조를 갖는 다당유도체로 이루어지는 분리제 |
| PT2308888T (pt) | 2001-11-14 | 2017-05-03 | Janssen Biotech Inc | Anticorpos anti-il-6, composições, métodos e utilizações |
| US7482436B2 (en) | 2002-08-30 | 2009-01-27 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of antibody |
| WO2004073741A1 (ja) | 2003-02-24 | 2004-09-02 | Chugai Seiyaku Kabushiki Kaisha | インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤 |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| AR045056A1 (es) | 2003-07-15 | 2005-10-12 | Amgen Inc | Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf |
| US20050100550A1 (en) | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| ATE464908T1 (de) | 2004-02-11 | 2010-05-15 | Warner Lambert Co | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern |
| AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| KR100595113B1 (ko) | 2005-03-07 | 2006-06-30 | 삼성에스디아이 주식회사 | 펌프 진동 및 소음 방지 구조가 구비된 연료 전지 시스템 |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| SI1960430T1 (sl) | 2005-12-09 | 2015-01-30 | Ucb Pharma, S.A. | Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6 |
| ATE550353T1 (de) * | 2005-12-30 | 2012-04-15 | Merck Patent Gmbh | Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| JP4743037B2 (ja) | 2006-07-28 | 2011-08-10 | 株式会社デンソー | 車両検出装置 |
| CN101563365B (zh) | 2006-08-03 | 2012-10-31 | 瓦西尼斯公司 | 抗-il-6单克隆抗体及其用途 |
| HUE048024T2 (hu) | 2006-08-10 | 2020-05-28 | Roy C Levitt | Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra |
| ES2433380T3 (es) | 2006-11-30 | 2013-12-10 | Medimmune Limited | Anticuerpos específicos para el complejo de interleucina 6 y el receptor de interleucina 6 |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| WO2008071685A1 (en) | 2006-12-13 | 2008-06-19 | Ablynx N.V. | Polypeptides specific for complexes involved in receptor-mediated signaling, such as the il-6/il-6 receptor complex |
| TWI363414B (en) | 2007-01-29 | 2012-05-01 | Touch Micro System Tech | Interposer for connecting a plurality of chips and method for manufacturing the same |
| MX2010012031A (es) | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
-
2009
- 2009-05-13 MX MX2010012031A patent/MX2010012031A/es active IP Right Grant
- 2009-05-13 EP EP09747432.4A patent/EP2297202B1/en active Active
- 2009-05-13 WO PCT/US2009/043734 patent/WO2009140348A2/en not_active Ceased
- 2009-05-13 CA CA2724279A patent/CA2724279C/en active Active
- 2009-05-13 JP JP2011509636A patent/JP2011520898A/ja active Pending
- 2009-05-13 ES ES09747432.4T patent/ES2564635T3/es active Active
- 2009-05-13 CN CN200980127494.7A patent/CN102089326B/zh active Active
- 2009-05-13 AU AU2009246430A patent/AU2009246430B2/en active Active
- 2009-05-13 US US12/465,295 patent/US8034344B2/en active Active
- 2009-05-13 DK DK09747432.4T patent/DK2297202T3/en active
-
2010
- 2010-11-11 IL IL209277A patent/IL209277A/en active IP Right Grant
-
2011
- 2011-09-07 US US13/227,157 patent/US8337849B2/en active Active
-
2012
- 2012-12-21 US US13/723,694 patent/US9234034B2/en active Active
-
2015
- 2015-03-25 JP JP2015062036A patent/JP6195586B2/ja active Active
-
2016
- 2016-01-12 US US14/993,153 patent/US9828430B2/en active Active
-
2017
- 2017-05-01 JP JP2017091252A patent/JP2017128613A/ja not_active Withdrawn
- 2017-11-27 US US15/823,086 patent/US10759862B2/en active Active
-
2020
- 2020-06-08 JP JP2020099264A patent/JP6923709B2/ja active Active
- 2020-07-31 US US16/944,828 patent/US11613582B2/en active Active
-
2021
- 2021-07-29 JP JP2021124411A patent/JP7297823B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11613582B2 (en) | Anti-IL-6/IL-6R antibodies and methods of use thereof | |
| US10982004B2 (en) | Anti-TLR4 antibodies and uses thereof | |
| US9650437B2 (en) | Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies | |
| CA2759848A1 (en) | Anti-il-17f antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140509 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD Year of fee payment: 16 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250509 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250509 |